Skip to main content
. 2022 Aug 18;13:957865. doi: 10.3389/fimmu.2022.957865

Figure 7.

Figure 7

Experimental verification of the combination and role of HEIH/YBX3 in colon cancer. (A) lncRNA HEIH pull-down. (B) Enrichment analysis of the pulled-down proteins. (C) Correlation between YBX3 expression in diverse clinical stages and prognosis in the colon cancer cohort. (D) HEIH expression level in various cancer stages quantified by qPCR. (E) YBX3 expression level in various cancer stages quantified by qPCR. (F) In SW620 cell line, lncRNA-HEIH knockdown enhanced the YBX3 expression confirmed by western blot. (G) Immunohistochemical staining of tissue microarray showing the YBX3 expression in different clinical pathological stages in magnifications of ×25, ×100, and ×200, respectively. *P<0.05; **P<0.01; ns, non-significant.